AbCellera Biologics Inc (ABCL) concluded trading on Thursday at a closing price of $3.14, with 4.24 million shares of worth about $13.3 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.60% during that period and on February 13, 2025 the price saw a gain of about 1.29%. Currently the company’s common shares owned by public are about 295.16M shares, out of which, 221.93M shares are available for trading.
Stock saw a price change of -4.56% in past 5 days and over the past one month there was a price change of 13.36%. Year-to-date (YTD), ABCL shares are showing a performance of 7.17% which decreased to -42.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.34 but also hit the highest price of $5.45 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 3.11 million. The stock is currently trading -1.92% below its 20-day simple moving average (SMA20), while that difference is up 3.07% for SMA50 and it goes to 4.33% higher than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 295.16M outstanding shares and institutions hold larger chunk of about 34.77% of that.
The stock has a current market capitalization of $927.45M and its 3Y-monthly beta is at 0.42. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 9.34 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 6.03% while standing at 6.58% over the month.
Stock’s fiscal year EPS is expected to drop by -15.13% while it is estimated to increase by 3.35% in next year.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
